ArticleAmerican journal of translational research2025
Benefit of nanohydroxyapatite combined with triamcinolone for non-surgical treatment of severe periodontitis: a retrospective study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the possible benefit of combining nanohydroxyapatite (nHA) with triamcinolone (TR) in the non-surgical management of severe periodontitis and to assess the influence of baseline inflammation on treatment outcomes.
methodsA retrospective analysis was conducted on 120 patients who received one of the following local treatments: nHA+TR, nHA alone, TR alone, or conventional subgingival scaling. All patients were followed for 6 months. Clinical data - including probing depth (PD), clinical attachment level (CAL), periodontal pocket closure rate, bleeding on probing (BoP), plaque index (PI), gingival index (GI), and gingival recession (GR) - along with inflammatory biomarkers [interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP)] were evaluated over the follow-up period. Correlation, regression, and subgroup analyses were performed.
resultsThe nHA+TR group showed the greatest improvements in PD, CAL, and pocket closure rate, along with significant reductions in IL-1β, TNF-α, IL-6, and CRP (all P < 0.01). Changes in PD and CAL were strongly correlated with declines in inflammatory markers (r > 0.80, both P < 0.001). Multivariable analysis identified combination therapy and higher baseline PD, PI, and BoP as positive predictors of clinical improvement, whereas elevated baseline CRP and IL-1β were associated with poorer outcomes (all P < 0.01). Treatment with nHA+TR was significantly associated with clinical success - defined as a ≥ 2 mm reduction in PD and ≥ 1 mm gain in CAL (odds ratio = 48.49; all P < 0.001). In patients with CRP > 3 mg/L, combination therapy showed enhanced clinical benefits, with a significant interaction between treatment and baseline inflammation (P_interaction = 0.032). All interventions were well tolerated, with no serious adverse events reported.
conclusionsThe combination of nHA and TR may enhance both clinical and inflammatory outcomes in the non-surgical treatment of severe periodontitis. Further randomized controlled trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.